Cardiac imaging in myocardial sarcoidosis and other cardiomyopathies

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 5, 2009, Pages 507-512

  Sharma, Sat ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

18F 2 fluoro 2 deoxyglucose positron emission tomography; Cardiac magnetic resonance imaging; Cardiac sarcoidosis

Indexed keywords

15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 123; CORTICOSTEROID DERIVATIVE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GALLIUM 67; RUBIDIUM 82; TECHNETIUM 99M; THALLIUM 201;

CARDIOMYOPATHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DISEASE COURSE; ECHOCARDIOGRAPHY; HEART MUSCLE BIOPSY; HEART SCINTISCANNING; HEMOCHROMATOSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MULTIDETECTOR COMPUTED TOMOGRAPHY; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CARDIOMYOPATHIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SARCOIDOSIS;

EID: 68949183120     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32832ea4c7     Document Type: Review

References (50)

1. Bernstein M, Konzlemann FW, Sidlick DM. Boeck's sarcoid: report of a case with visceral involvement. Arch Intern Med 1929; 44:721-734.
2. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 1977; 63:86-108.
3. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978; 58:1204-1211.
4. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995; 119:167-172.
5. Fleming HA. Cardiac sarcoidosis. Semin Respir Med 1986; 8:65-71.
6. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest 1993; 103:253-258.
7. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society, European Respiratory Society, World Association on Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:149-173. (Pubitemid 29469097)
8. Longcope WT, Friedman DG. A study of sarcoidosis based on a combined investigation of 160 cases including 30 autopsies from the Johns Hopkins Hospital and Massachusetts General Hospital. Medicine 1952; 31:1-132.
9. Haywood LJ, Sharma OP, Siegel ME, et al. Detection of myocardial sarcoidosis by thallium 201 imaging. J Natl Med Assoc 1982; 74:959-964.
10. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005; 45:1683-1690.
11. Tadamura E, Yamamuro M, Kubo S, et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. Am J Roentgenol 2005; 185:110-115.
12. OkumuraW, Iwasaki T, Toyama T, etal. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004; 45:1989-1998.
13. Momose M, Kadoya M, Koshikawa M, etal. Usefulness of 67Ga SPECT and integrated low-dose CT scanning (SPECT/CT) in the diagnosis of cardiac sarcoidosis. Ann Nucl Med 2007; 21:545-551.
14. Kaminaga T, Takeshita T, Yamauchi T, et al. The role of iodine-123-labeled 15-(p-iodophenyl)-3R,S-methylpentadecanoic acid scintigraphy in the detection of local myocardial involvement of sarcoidosis. Int J Cardiol 2004; 94:99-103.
15. Rehwald WG, Fieno DS, Chen EL, et al. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible is-chemic injury. Circulation 2002; 105:224-229.
16. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343:1445-1453.
17. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999; 100:1992-2002.
18. Shimada T, Shimada K, Sakane T, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001; 110:520-527.
19. Klein C, Nekolla SG, Bengel FM, et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation 2002; 105:162-167.
20. Hirose Y, Ishida Y, Hayashida K, et al. Myocardial involvement in patients with sarcoidosis: an analysis of 75 patients. Clin Nucl Med 1994; 19:522-526.
21. Nazarian S, Roguin A, Zviman MM, etal. Clinical utility and safety of a protocol for noncardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantable-cardioverter defibrillators at 1.5 tesla. Circulation 2006; 114:1277-1284.
22. Chandra M, Silverman ME, Oshinski J, Pettigrew R. Diagnosis of cardiac sarcoidosis aided by MRI. Chest 1996; 110:562-565.
23. Doherty MJ, Kumar SK, Nicholson AA, McGivern DV. Cardiac sarcoidosis: the value of magnetic resonance imaging in diagnosis and assessment of response to treatment. Respir Med 1998; 92:697-699.
24. Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest 2002; 122:1895-1901.
25. Ichinose A, Otani H, Oikawa M, et al. MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. Am J Roentgenol 2008; 91:862-869.
26. Manins V, Habersberger J, Pfluger H, Taylor AJ. Cardiac magnetic resonance imaging in the evaluation of cardiac sarcoidosis: an Australian single-centre experience. Intern Med J 2009; 39:77-82.
27. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with predni-sone. Am J Cardiol 2001; 88:1006-1010.
28. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with 13N-NH3/18F-FDG PET. J Nucl Med 2003; 44:1030-1036.
29. Ishimaru S, Tsujino I,Takei T, etal. Focal uptake of 18f-fluoro-2- deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005; 26:1538-1543. (Pubitemid 41373496)
30. Pandya C, Brunken RC, Tchou P, et al. Detecting cardiac involvement in sarcoidosis: a call for prospective studies of newer imaging techniques. Eur Respir J 2007; 29:418-422.
31. Tellier P, Paycha F, Antony I, et al. Reversibility by dipyridamole of thallium-201 myocardial scan defects in patients with sarcoidosis. Am J Med 1988; 85:189-193.
32. Tellier P, Valeyre D, Nitenberg A, et al. Cardiac sarcoidosis: reversion of myocardial abnormalities by dipyridamole. EurJ Nucl Med 1985; 11:201-204.
33. Mana J. Nuclear imaging: 67-gallium, 201-thallium, 18F-labeledfluoro-2- deoxy-D-glucose positron emission tomography. Clin Chest Med 1997; 18:799-812.
34. OkayamaK, Kurata C, Tawarahara K, etal. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest 1995; 107:330-336.
35. Kiuchi S, Teraoka K, Koizumi K, etal. Usefulness of late gadolinium enhancement combined with MRI and 67-Ga scintigraphy in the diagnosis of cardiac sarcoidosis and disease activity evaluation. Int J Cardiovasc Imaging 2007; 23:237-242.
36. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008; 133:1426-1435.
37. Kinney EL, Caldwell JW. Do thallium myocardial perfusion scan abnormalities predict survival in sarcoid patients without cardiac symptoms? Angiology 1990; 41:573-576.
38. Vignaux O, Dhote R, Duboc D, et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr 2002; 26:762-767.
39. Mahrholdt H, Wagner A, Judd RM, etal. Delayed enhancement cardiovascular magnetic resonance assessment of nonischaemic cardiomyopathies. Eur Heart J 2005; 26:1461-1469.
40. Arrive L, Assayag P, Russ G, et al. MRI and cine MRI of asymmetric septal hypertrophic cardiomyopathy. J Comput Assist Tomogr 1994; 18:376-381.
41. von Kemp K, Bechers R, Vandenweghe J, et al. Echocardiography and magnetic resonance imaging in cardiac amyloidosis. Acta Cardiol 1989; 49:29-33.
42. Arrive Let al, Moon JC, McKenna WJ, McCrohon JA, et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41:1561-1567.
43. Tanner MA, He T, Westwood MA, et al. Multicenter validation of the transfer-ability of the magnetic resonance T2# technique for the quantification of tissue iron. Haematologica 2006; 91:1388-1393.
44. Anderson LJ, Holden S, Davis B, etal. CardiovascularT2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22:2171-2174.
45. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2# cardiovascular magnetic resonance. Br J Haematol 2004; 127:348-353.
46. Celletti F, Fattori R, Napoli G, etal. Assessment of restrictive cardiomyopathy of amyloid or idiopathic etiology by magnetic resonance imaging. Am J Cardiol 1999; 83:798-804.
47. Friedrich MG, Strohm O, Schulz-Menger J, et al. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 1998; 97:1802-1806.
48. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004; 109:1250-1255.
49. Laissy JP, Messin B, Varenne O, et al. MRI of acute myocarditis: a comprehensive approach based on various imaging sequences. Chest 2002; 122:1638-1642.
50. Ingkanisorn WP, Rhoads KL, Aletras AH, et al. Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction. J Am Coll Cardiol 2004; 43:2253-2257.